# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...
Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reve...